PURPOSE:

• The original WHI trials were designed to assess risk vs benefits of menopausal hormone therapy
• Double-blinded, placebo-controlled, randomized clinical trials, conducted among US postmenopausal women aged 50 to 79 years at enrollment using the following 2 drug regimens
  • Conjugated equine estrogens (CEE) plus medroxyprogesterone acetate (MPA) for women with an intact uterus
  • CEE alone for women with hysterectomy
• The CEE plus MPA trial was stopped early (after 5.6 years) due to an increased risk of breast cancer and overall risks exceeding benefits
• CEE-alone trial was stopped after 7.2 years due to an increased risk of stroke
• Postintervention follow up has been ongoing
• Manson et al. (JAMA, 2017) report the extended follow up on all-cause and cause-specific mortality with attention to age

METHODS:

• Postintervention follow up study of the two WHI studies (1993-1998)
• Total 27,347 postmenopausal women ages 50 to 79 years were recruited at 40 US clinical centers
  • 16,608 women with a uterus received daily oral CEE (0.625 mg) plus MPA (2.5 mg) or placebo
  • 10,739 women with hysterectomy received daily oral CEE (0.625 mg) alone or placebo
• Primary outcome: All-cause mortality
  • Cause-specific mortality (cardiovascular disease cancer and other major causes)
• 18 year follow up in 2 trials separately and combined (pooled)

RESULTS:

• All-cause mortality
  • Pooled cohort: 27.1% in the hormone therapy group vs 27.6% in the placebo group (hazard ratio [HR], 0.99 [95% CI, 0.94-1.03])
  • CEE plus MPA: HR 1.02 (95% CI, 0.96-1.08)
  • CEE alone: HR 0.94 (95% CI, 0.88-1.01)
• Cardiovascular mortality
  • Pooled cohort: HR 1.00 (95% CI, 0.92-1.08)
• Total cancer mortality
  • Pooled cohort: HR 1.03 (95% CI, 0.95-1.12)
• Other causes
  • Pooled cohort: HR 0.95 (95% CI, 0.88-1.02)
  • results did not differ significantly between trials
• Comparing younger women (50-59 years) to older women (70-79 years) in the pooled cohort for all-cause mortality
  • During intervention phase: all-cause mortality reduced compared to older women
    • ratios of HRs 0.61 (95% CI, 0.43-0.87)
  • During cumulative 18-year follow-up: no difference seen in all-cause mortality compared to older women
    • ratios of HRs 0.87 (95% CI, 0.76-1.00)
  • No significant difference between trials

CONCLUSION:

• There was no long-term association between hormone replacement and all-cause or cause-specific mortality during a follow up period of 18 years in women who used combination estrogen plus progestin for 5.6 or estrogen-alone group for 7.2 years
• Limitations include specific hormone replacement formulations and therefore results may not be generalizable
• Cause-specific mortality results should be considered exploratory because multiple smaller subgroups were analyzed
• The accompanying editorial states that this present study supports the recently released 2017 NAMS guidance and women should be reassured and hormone therapy appears “safe and efficacious”.

Learn More – Primary Sources:

Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women’s Health Initiative Randomized Trials

Menopausal Hormone Therapy: Understanding Long-term Risks and Benefits (JAMA Editorial)

Related ObG Topics:

North American Menopause Society Releases Hormone Therapy Statement

Early-Onset Menopause – Increased Risk of Cardiovascular Disease?

Treating Postmenopausal Vaginal Atrophy When Estrogen is Not an Option

Does Estrogen Therapy Have Cardiovascular Benefit in Early Postmenopause?

Does Hormone Therapy Protect Against Alzheimer’s?